TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Decompensated Heart Failure
Conditions
Acute Decompensated Heart Failure
Trial Timeline
Dec 1, 2013 → Sep 1, 2016
NCT ID
NCT01966601About TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo is a phase 2 stage product being developed by Trevena for Acute Decompensated Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT01966601. Target conditions include Acute Decompensated Heart Failure.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01966601 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Decompensated Heart Failure